Lilly Plans To File Arxxant NDA On Strength Of Single Phase III Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly will include only one Phase III study in an application for Arxxant use for diabetic retinopathy, the firm said